

James William Darnowski, Ph.D.

PUBLICATIONS

1. Darnowski JW, Sawyer RC, Stolfi RL, Martin DS and Lau-Cam CA. Decreased host toxicity in vivo during chronic treatment with 5-fluorouracil. *Cancer Chemother Pharmacol* 14:63-69, 1985.
2. Darnowski JW and Handschumacher RE. Tissue specific enhancement of uridine utilization and 5-fluorouracil therapy by benzylacyclouridine. *Cancer Res* 45:5364-5368, 1985.
3. Darnowski JW and Handschumacher RE. Tissue uridine pools: Evidence in vivo for the active transport of uridine. *Cancer Res* 46:3490-3494, 1986.
4. Darnowski JW, Holdridge C and Handschumacher RE. Concentrative uridine transport by murine splenocytes: Kinetics, substrate specificity and sodium dependency. *Cancer Res* 47:2614-2619, 1987.
5. Darnowski JW and Handschumacher R. Benzylacyclouridine, pharmacokinetics metabolism and biochemical effects in mice. *Biochem Pharmacol* 37:2613-2618, 1988.
6. Darnowski JW and Handschumacher RE. Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. *Pharmacol and Therapeutics* 41:381-392, 1989.
7. Brunetti I, Falcone A, Calabresi P, Goulette FA and Darnowski JW. 5-Fluorouracil enhances azidothymidine cytotoxicity. In vitro, in vivo and biochemical studies. *Cancer Res* 50:4026-4031, 1990.
8. Calabresi P, Falcone A, St. Clair MH, Wiemann MC, Chu SH and Darnowski JW. Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-HIV activity. *Blood*,76:2210-2215, 1990.
9. Falcone A, Darnowski JW, Chu SH, Brunetti I, Ruprecht RM and Calabresi P. Azidothymidine antiretroviral efficacy in mice is modulated by the concomitant administration of benzylacyclouridine or uridine. *Blood*,76:2216-2221, 1990.
10. el Kouni MH, Naguib FNM, Park KS, Cha S, Darnowski JW and Soong SJ. Circadian rhythm of hepatic uridine phosphophorylase and plasma uridine concentration in mice. *Biochem Pharmacol*,40:2479-2485, 1990.

11. Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Cummings FJ, Clark J, Browne MJ, Beitz J, Weitberg AB. Oral Azidothymidine, continuous infusion 5-fluorouracil and oral leucovorin: A Phase I Study. *J Natl Cancer Inst*, 82:1710-1714,1990.
12. Darnowski JW, Handschumacher RE, Abate RA, Goulette FA and Calabresi P. Tissue-specific expansion of uridine pools in mice. Effect of benzylacyclouridine, dipyridamole and exogenous uridine. *Biochem Pharmacol*,41:2031-2036,1991.
13. Chu, E, Chu, MY, Darnowski, JW, Chen, ZH, Pan, BC, and Chu, SH. Enhancement of 5-fluoro-2'-deoxyuridine antineoplastic activity by benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma line. *Cancer Res.*, 52:1729-1736, 1992.
14. Tosi, P, Calabresi, P, Goulette, F, Renaud, C and Darnowski, JW. 3'-Azido-3'-deoxythymidine antineoplastic activity is enhanced by methotrexate in vitro and in vivo. *Cancer Res.*, 52:4069-4073, 1992.
15. Posner, MR, Darnowski, JW, Weitberg, AB, Corvese, D, Cummings, FJ, Clark, J, Murry, C, Goulette, F, Clendenin, N, Bigley, J, and Calabresi, P. A phase I clinical and pharmacokinetic study of high dose intravenous zidovudine with 5-fluorouracil and leucovorin. *Cancer*, 70:2929-2934, 1992.
16. Turk, PS, Leenen, L, Darnowski, JW, Belliveau, J, Weinberg, MC, and Wanebo, HJ. Comparison of isolated pelvic perfusion, open pelvic perfusion, and pelvic arterial infusion with charcoal perfusion in a canine model. *Reg. Cancer Treat.*, 1: 1-3, 1993.
17. Turk, PS, Belliveau, JF, Darnowski, JW, Weinberg, MC, Leenen, L and Wanebo, HJ. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. *Arch. Surg.*,128: 533-539, 1993.
18. Tosi, P, Visani, G, Ottaviani, E, Tura, S and Darnowski, JW. Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. *Eur. J. Hematol.*,52: 291-295, 1994.
19. Darnowski, JW and Goulette, FA. 3'-Azido-3'-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. *Biochem. Pharmacol.*,48: 1797-1805, 1994.
20. Beitz, JG, Darnowski, JW, Cummings, FJ, Browne, MJ, Clark, JW, Bigley, JW and Weitberg, AB. Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. *Cancer Invest.*, 13:464-469, 1995.

21. Marchbanks, K, Dudley, MN, Posner, MR and Darnowski, J. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. *Pharmacother.*, 15:451-457, 1995.
22. Sharma, M, Jain, R, Azadnia, A, Ionescu, E and Darnowski, JW. Quantitative analysis of 3'-azido-3'-deoxythymidine incorporation into DNA in human colon tumor (HCT-8) cells. *Bioconjugate Chem.*, 6:536-540, 1995.
23. Davol, PA, Goulette, FA, Frackelton, ARJr and Darnowski, JW. Modulation of p53 expression by human recombinant interferon alpha-2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. *Cancer Res.*, 56:2522-2526, 1996.
24. Rana, KZ, Darnowski, JW, Strayer, AH and Dudley, MN. Clarithromycin does not affect the phosphorylation of zidovudine in vitro. *Antimicrob. Agents Chemother.*, 40:1945-1947, 1996.
25. Clark, J, Sikov, W, Cummings, F, Browne, M, Akerley, M, Wanebo, H, Weitberg, A, Kennedy, T, Cole, B, Bigley, J, and Darnowski, J. Phase II study of 5-fluorouracil, leucovorin and azidothymidine in patients with metastatic colorectal cancer. *J. Cancer Res. Clin. Oncol.*, 122: 554-558, 1996.
26. Darnowski, JW, Davol, PA and Goulette, FA. Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. *Biochem. Pharmacol.*, 53:571-580, 1997.
27. Pizzorno, G, Yee, L, Burtness, BA, Marsh, JC, Darnowski, JW, Chu, MYW, Chu, SH, Chu, E, Leffert, JJ, Handschumacher, RE and Calabresi, P. Phase I clinical and pharmacological studies of benzylacyclouridine (BAU), a uridine phosphorylase inhibitor. *Clinical Cancer Res.*, 4:1165-1175, 1998.
28. Whartenby, KA, Darnowski, JW, Freeman, SM, Yurasha, K and Calabresi, P. Recombinant interferon alpha 2a synergistically enhances ganciclovir-mediated tumor cell killing in the Herpes Simples virus thymidine kinase system. *Cancer Gene Therapy*, 6:402-408, 1999.
29. Ribizzi, I., Darnowski, J.W., Goulette, F.A., Sertoli, M.R. and Calabresi, P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. *Leukemia Res.*, 24:519-525, 2000.
30. Calabresi, P., Goulette, F.A. and Darnowski, J.W. Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. *Cancer Res.*, 61:6816-6821, 2001.

31. Ribizzi, I., Darnowski, J.W., Goulette, F.A., Akhtar, M.S., Chatterjee, D. and Calabresi, P. Taurolidine: Preclinical evaluation of a novel, highly selective, agent for bone marrow purging. *Bone Marrow Transpl.*, 29:313-319, 2002.
32. Han, Z., Wei, W., Dunaway, S., Darnowski, J.W., Calabresi, P., Sedivy, J., Hendrickson, E.A., Balan, K.V., Pantazis, P. and Wyche, J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. *J. Biol. Chem.*, 277: 17154-17160, 2002.
33. Han, Z., Ribizzi, I., Darnowski, J.W., Pantazis, P., Wyche, J.H. and Calabresi, P. The novel antineoplastic drug Taurolidine induces apoptosis by a mitochondrial-dependent mechanism in the HL60 cell line. *Anticancer Res.*, 22: 1959-1964, 2002.
34. Whartenby, K.A., Darnowski, J.W., Freeman, S.M. and Calabresi, P. A role for MAP kinase in the antitumor activity of a nucleoside analogue. *Cancer Gene Therap.*, 9: 37-43, 2002.
35. Allegrini, G., Goulette, F.A., Darnowski, J.W. and Calabresi, P. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. *Cancer Chemother. Pharmacol.*, 53:261-266, 2004.
36. Chatterjee, D., Roy, R., Braastad, C., Mott, S., Sun, Y., Mukhopadhyay, A., Aggarwal, B., Darnowski, J., Wyche, J.H., Pantazis, P., Wyche, J.H., Sedivy, J.M. and Yeung, K. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. *J. Biol. Chem.*, 279: 17515-17523, 2004
37. Chatterjee, D., Goldman, M., Braastad, C., Darnowski, J., Whyche, J.H., Pantazis, P. and Goodglick, L. The role of 14-3-3 ζ expression in resistance of prostate cancer cells to 9-nitrocamptothecin. *Int. J. Oncol.*, 25: 503-509, 2004.
38. Darnowski, J.W., Goulette, F.A., Chatterjee, D., Cousens, L.P. and Calabresi, P. Mechanistic and antineoplastic evaluation of Taurolidine in the DU145 model of human prostate cancer. *Cancer Chemother. Pharmacol.*, 54: 249-258, 2004.
39. Cousens, L.P., Goulette, F.A., Calabresi, P. and Darnowski, J.W. IFN α -mediated signaling inhibits Fas Ligand-induced apoptosis independent of de novo protein synthesis. *J. Immunol.*, 174: 320-327, 2005.
40. Darnowski, J. W., Cousens, L.P., Chatterjee, D. and Goulette, F. A. STAT protein demolition by caspases: cellular and functional analysis. *J. Biol. Chem.*, under final revision.

PUBLICATIONS IN PREPARATION:

1. Sartore-Bianchi, A., Nici, L., Chatterjee, D., Porta, C., Gaudino, G., Mutti, L. and Darnowski, J. W. Preclinical evaluation of the proteasome inhibitor Bortezomib in malignant mesothelioma. Clin. Cancer Res., submitted.
2. Chatterjee, D., Braastad, C., Goulette, F., Mott, S., Earl, T., Calabresi, P. and Darnowski, J. Stat3 expression is down-regulated during CD95-triggered apoptosis. Manuscript in preparation.

ABSTRACTS

1. Darnowski J, Stolfi R, Sawyer R, Martin D and Lau-Cam C. In vivo modification of 5-fluorouracil (FUra) induced toxicity by chronic treatment with the drug. Proc Am Assoc Cancer Res 24:302, 1983.
2. Darnowski JW and Handschumacher RE. Pharmacokinetics of benzylacyclouridine (BAU) and its utility as a potential rescuing agent from 5-fluorouracil (FUra) induced toxicity. Proc Am Assoc Cancer Res 25:358, 1984.
3. Darnowski JW and Handschumacher RE. Enhanced therapeutic effectiveness of fluorouracil when combined with benzylacyclouridine reflects altered uridine metabolism. Proc Am Assoc Cancer Res 26:326, 1985.
4. Trautmann T, Chang PK, Reddy A, Holdrige C, Darnowski J and Handschumacher RE. 5'-Pyrimidine nucleoside derivatives as potential probes in normal and defective transport. Proc Am Assoc Cancer Res 26:265, 1985.
5. Darnowski JW and Handschumacher RE. Active uridine (Urd) transport; A potential target for chemotherapy. Proc Am Assoc Cancer Res 27:25, 1986.
6. Darnowski JW and Handschumacher RE. Tissue specific active nucleoside transport and its relationship to pyrimidine metabolism in neoplastic cells. Proc Am Assoc Cancer Res 28:15, 1987.
7. Sobrero A, Pizzorno G, Romanini A, Russello O, Rosso R, Civalleri D, Simoni G, Darnowski J and Handschumacher RE. Plasma and tissue uridine (Urd) levels in canine and human subjects. Proc Am Assoc Cancer Res 28:413, 1987.
8. Darnowski JW and Handschumacher RE. Manipulation of tissue uridine pools with benzylacyclouridine and dipyrnidamole modifies fluorouracil therapy. Proc Am Assoc Cancer Res 29:474, 1988.
9. Calabresi P, Falcone A, Wiemann M, Chu M, Chu S-H and Darnowski J. Beneficial effects of benzylacyclouridine and dipyrnidamole on 3'-azido-3'-deoxythymidine-induced anemia. Proc Am Coll Clin Pharmacol 17:945, 1988.

10. Darnowski JW, Falcone A, Brunetti I, Chu M, Chu S and Calabresi P. Tissue uracil nucleotide pools: Potential role in fluorouracil activity. Proc Am Assoc Cancer Res 30:564, 1989.
11. Falcone A, Darnowski JW, Wiemann MC, Brunetti I and Calabresi P. Uridine to rescue AZT bone-marrow toxicity in vivo. Proc Am Assoc Cancer Res 30:570, 1989.
12. Brunetti I, Darnowski JW, Falcone A, Johnson KA and Calabresi P. Azidothymidine enhances fluorouracil and methotrexate antitumor and therapeutic activity. Proc Am Assoc Cancer Res 30:595, 1989.
13. Pizzorno G, Darnowski JW, Abate RA, Sam JV, Calabresi P and Handschumacher RE. Pharmacokinetic and biochemical evaluation of benzylacetylouridine in dogs. Proc Am Assoc Cancer Res 30:541, 1989.
14. Brunetti I, Falcone A, Calabresi P, Goulette F and Darnowski JW. Fluorouracil enhances azidothymidine antineoplastic activity and incorporation into tissue nucleic acids. Proc Am Assoc Cancer Res 31:401, 1990.
15. Darnowski JW, Brunetti I, Posner M, Weitberg A, Falcone A, Goulette F, Corvesi D and Calabresi P. Fluorouracil plus azidothymidine cytotoxicity in vitro: Relationship to cellular thymidine kinase. Proc Am Assoc Cancer Res 31:398, 1990.
16. Posner MR, Darnowski J, Weitberg AB, Brunetti I, Curt G, Clark J, Cummings F, Browne M, Corvese D and Calabresi P. A Phase I trial of Azidothymidine (AZT) and 5-Fluorouracil (FU) with Leucovorin (L) (AFL-1). Proc Am Soc Clin Oncol 9:67, 1990.
17. Falcone A, Clark JW, Darnowski JW, Zinzani PL, Brunetti and Calabresi P. Synergistic antitumor activity of suramin and recombinant Alfa-2A interferon (IFN) against human colon cancer cell lines. Am Soc Clin Oncol 9:110, 1990.
18. Calabresi P and Darnowski JW. Fluorouracil enhances azidothymidine anti-retroviral activity in vivo. Proc Am Fed Clin Res 38:779A, 1990.
19. Darnowski JW, Tosi P and Calabresi P. Fluorouracil enhances azidothymidine antiretroviral activity in the Rauscher Murine leukemia virus model. Proc Amer Soc Hematol. (Blood) 76 (Suppl.1):485a, 1990.
20. Tosi P, Darnowski JW and Calabresi P. Methotrexate (MTX) enhances the cytotoxic and antineoplastic of 3'-azido-3'-deoxythymidine (AZT). Proc Am Soc Hematol. (Blood) 76 (Suppl.1):329a, 1990.

21. Darnowski JW, Tosi P, Goulette F, Renaud C and Calabresi P. Relationship between 3'-azido-3'-deoxythymidine (AZT)-induced cytotoxicity in human colon tumor cells and the utilization of AZTTP in DNA synthesis. 7th Internatl Conf. on Chemical Modifiers of Cancer Treatment. p103, Abs B15, 1991.
22. Leith, JT, Darnowski, JW, Coachman, N, Calabresi, P and Glicksman, AS. Effects of 5-fluorouracil and azidothymidine on in vitro x-ray sensitivity of HCT-8 human colon cancer cells. 7th International Conf. on Chemical Modifiers of Cancer Treatment. p96-97, Abs B11, 1991.
23. Posner, MR, Darnowski, JW, Dudley, M, Weitberg, A and Calabresi, P. A phase I clinical and pharmacokinetic study of azidothymidine (AZT), 5-fluorouracil (FUra) and leuco- vorin (L): A therapy based on the biochemical modulation of azidothymidine metabolism. 7th International Conf. on Chemical Modifiers of Cancer Treatment. p111-112, Abs B19, 1991.
24. Posner, MR, Darnowski, JW, Cummings, FJ, Clendeninn, N, Bigley, J, Murray, C, Weitberg, AB and Calabresi, P. A phase I study of high dose, continuous infusion intravenous zidovudine and 5-fluorouracil with calcium leucovorin. Proc. Amer. Assoc. Clin. Oncol.,10: A474, 1991.
25. Darnowski, JW, Renaud, CA, Chu, M, Goulette, FA, Tosi, P and Calabresi, P. Resistance to Azido-thymidine cytotoxicity in the human colon tumor cell line HCT15 is associated with enhanced removal of AZT from cellular DNA. Proc. Amer. Assoc. Cancer Res.,32: 358, 1991.
26. Tosi, P, Calabresi, P, Goulette, FA, Renaud, CA and Darnowski, JW. Methotrexate enhances 3'-azido-3'-deoxythymidine antineoplastic activity. Proc. Amer. Assoc. Cancer Res., 32:342, 1991.
27. Leith, JT, Darnowski, JW, Coachman, N, Calabresi, P, and Glicksman, AS. Effects of 5-fluorouracil and azidothymidine on in vitro sensitivity of HCT-8 human colon tumor cells to X-rays. Proc. Amer. Assoc. Cancer Res.,32:413, 1991.
28. Rowley, KA, Dudley, MN, Darnowski, JW, and Posner, MR. Pharmacokinetics (PK) of high-dose zidovudine administered as a continuous infusion. Proc. ICAAC., 31:A759,1991.
29. Clark, JW, Santos, AA and Darnowski, JW Extracellular guanosine enhances vitamin D₃ induced differentiation of the human CML cell line RWLeu4. Proc. Amer. Assoc. Cancer Res., 33:47, 1992.
30. Beitz, JG, Darnowski, JW, Cummings, FJ, Browne, M, Clark, J, Bigley, J and Weitberg, A A phase I and pharmacologic analysis of fluorouracil + leucovorin combined with infused high-dose zidovudine. Proc. Amer. Assoc. Cancer Res., 33:427, 1992.

31. Darnowski, JW and Goulette, FA Fluorouracil increases azidothymidine cytotoxicity by altering dTTP pools. Proc. Amer. Assoc. Cancer Res., 33:421, 1992.
32. Turk, PS, Belliveau, JF, Darnowski, JW, Cummings, FJ and Wanebo, HJ. Localized pelvic infusion with charcoal hemofiltration and 5-FU and cisplatin in the canine model: potential for selective therapy of pelvic malignancy. Proc. Amer. Assoc. Cancer Res., 33:447, 1992.
33. Turk, PS, Belliveau, JF, Darnowski, JW and Wanebo, HJ. Comparison of a hemoperfusion charcoal filter versus a hemofiltration dialyzer for reducing blood levels of cis-platinum. Metal Ions Med.,2:240-241, 1992.
34. Darnowski, JW, Paulos, M, Santos-Moore, A, Linakis, J, and Goulette, FA. Extended exposure to the antibiotic chloramphenicol appears to induce multi-drug resistance in a human CML line. Proc. Amer. Assoc. Cancer Res., 34:315, 1993.
35. Darnowski, JW and Goulette, FA. Increased azidothymidine metabolism in presence of fluorouracil reflects increased thymidine kinase activity. Proc. Amer. Assoc. Cancer Res., 34:302, 1993.
36. Beitz, J, Davol, P, Darnowski, J, Lappi, DA, and Baird, A. Combination of FGF-SAP mitotoxin and cis-platin in the treatment of human melanoma. Proc. Amer. Assoc. Cancer Res., 34:342, 1993.
37. Posner, M, Darnowski, J, Tessitore, J, Bigley, J, Parker, L, Stuart, K, Huberman, M. A phase I trial of high dose, intravenous zidovudine (AZT) and 5-fluorouracil/leucovorin (FUra/L). Proc. Amer. Soc. Clin. Oncol.,12:162, 1993.
38. Browne, MJ, Beitz, J, Clark, JW, Cummings, FJ, Weitberg, A, Murray, C, and Darnowski, JW. A phase I study of zidovudine (AZT) combined with methotrexate in patients (pts) with advanced cancer. Proc. Amer. Soc. Clin. Oncol.,12:163, 1993.
39. Darnowski, JW and Goulette, FA. Synergistic cytotoxicity with alpha-interferon and azidothymidine in HCT-8 cells reflects increased azidothymidine incorporation in DNA. Proc. Amer. Assoc. Cancer Res.,35:334, 1994.
40. Rana, KZ, Darnowski, JW, Copeland, DA, Strayer, AH, Pivarnik, PE and Dudley, MN. Clarithromycin (CLR) does not affect intracellular levels of phosphorylated zidovudine(ZVD) metabolites. Proc. Internatl. Conf. Antimicrob. Agents Chemotherap.,34:211,1994.
41. Rana, KZ, Darnowski, JW, Dudley, MN, Drusano, GL and Bilello, JA. Exposure to hydroxyurea in combination with zidovudine does not increase activity against HIV in vitro. 2nd Natl. Conf. Human Retroviruses Rel. Infect., p69, 1995.

42. Tosi, P, Gherlinzoni, F, Visani, G, Mazza, P, Zinzani, PL, Coronado, O, Chiodo, F, Darnowski, JW and Tura, S. Zidovudine as an antineoplastic agent in the treatment of HIV related high-grade non Hodgkin lymphoma. Proc. Amer. Soc. Hematol., accepted November 1994.
43. Darnowski, JW, Hankinson, G and Goulette, FA. Alpha-interferon induced inhibition of DNA repair increases the cytotoxicity of azidothymidine in HCT-8 cells. Proc. Amer. Assoc. Cancer Res.,36:298, 1995.
44. Darnowski, JW, Davol, P, Ahsanuddin, AN and Goulette, FA. Resistance to azidothymidine in HCT-15 cells reflects altered DNA repair processes and is associated with increased wild-type p53 expression. Proc. Amer. Assoc. Cancer Res.,36:329, 1995.
45. Clark, JW, Cummings, F, Sikov, W, Browne, M, Akerley, W, Wanebo, H, Weitberg, AB, Kennedy, T, Bigley, J and Darnowski, JW. Phase II study of 5-fluorouracil (5-FU), leucovorin (LV) and azidothymidine (AZT) in patients with metastatic colorectal cancer. Proc. Amer. Soc. Clin. Oncol., 14:220, 1995.
46. Darnowski, JW, Davol, PA and Goulette, FA. Human recombinant interferon alpha-2a disrupts polymerase beta-mediated DNA repair to sensitize HCT-8 cells to the DNA damaging agent azidothymidine. Proc. Amer. Assoc. Cancer Res., 37:358, 1996.
47. Davol, PA, Goulette, FA and Darnowski, JW. Modulation of p53 by human recombinant interferon alpha-2a and its effects on cisplatin resistance in a human melanoma cell line. Proc. Amer. Assoc. Cancer Res., 37:330, 1996
48. Darnowski, JW, Davol, PA, Goulette, FA and Calabresi, P. Association of p53 protein and DNA polymerase beta: Preliminary metabolic and functional analysis. Proc. New Engl. Cancer Soc., 57: 27, 1996.
49. Darnowski, JW, Goulette, FA, Calabresi, P. Human recombinant interferon alpha-2a enhances the cytotoxicity of the DNA damaging agent 3'-azido-3'-deoxythymidine in the human prostate carcinoma cell line DU145. Proc. New Engl. Cancer Soc., 57: 51, 1996.
50. Darnowski, JW, Leith, JT, Goulette, FA, Davol, PA, Calabresi, P. Human recombinant interferon alpha-2a enhances the cytotoxicity on ionizing radiation in DU145 human prostate carcinoma cells. Proc. Amer. Assoc. Cancer Res., 38:427, 1997.
51. Davol, PA, Goulette, FA, Frackelton, ARJr, Darnowski, JW. Association of p53 protein with DNA polymerase beta in human melanoma: Evidence for a role in p53-regulated G₁ arrest in response to DNA damage. Proc. Amer. Assoc. Cancer Res., 38:638, 1997.

52. Darnowski, JW, Goulette, FA, Leith, JA and Calabresi, P. Human recombinant interferon alpha-2a (rIFN-a2a) disrupts the cell cycle and increases the cytotoxicity of ionizing radiation (IR) in DU145 human prostate cancer cells. Proc. Amer. Assoc. Cancer Res., 39:280, 1998.
53. Ribizzi, I, Darnowski, JW, Goulette, FA and Calabresi, P. Synergistic cytotoxicity of azidothymidine (AZT) plus interferon alpha-2a (IFN) in a human myelodysplastic syndrome cell line. Proc. Amer. Assoc. Cancer Res., 39:643, 1998.
54. Yee, LK, Chu, E, Pan, BC, Chu, MY, Darnowski, J, Chu, SH, and Calabresi, P. A phase I clinical trial of benzylacetylouridine (BAU) as a biochemical modulator of 5-fluorouracil (5-FU). Proc. Amer. Assoc. Cancer Res., 39: 321, 1998.
55. Hooda, B., Forman, E., Calabresi, P, Goulette, F and Darnowski, J. Interferon exposure increases poly (ADP-ribose) polymerase expression in T98G cells and reduces sensitivity to DNA damage. Proc. Soc. Neuro-Oncol.35:365, 1998.
56. Whartenby, K.A., Darnowski, J.W., Freeman, S.M., Yurasha, K. and Calabresi, P. Mechanisms of synergistic action of IFN and GCV in the HSV-TK tumor system. Internatl. Conf. Gene Therap., 1998.
57. Darnowski, JW, Goulette, FA, Whartenby, KA and Calabresi, P. Increased poly (ADP-ribose) polymerase expression, activity and sensitivity to ionizing radiation in DU145 cells exposed to human recombinant interferon alpha-2a. Proc. Amer. Assoc. Cancer Res., 40: 402, 1999.
58. Whartenby, K.A., Darnowski, J.W., Freeman, S.M. and Calabresi, P. Mechanisms of enhanced killing of alpha-interferon (aIFN) and ganciclovir (GCV) on tumor cells in the herpes simplex thymidine kinase (HSV-TK) system. Proc. Amer. Assoc. Cancer Res., 40: 596, 1999.
59. Whartenby, K.A., Darnowski, J.W., Freeman, S.M. and Calabresi, P. The role of MAP kinases in GCV-mediated tumor cell death in the HSV-TK system. Proc. Amer. Assoc. Cancer Res., 41: 380, 2000.
60. Calabresi, P., Goulette, F.A. and Darnowski, J.W. Antineoplastic effects of taurolidine in human tumor cell lines. Proc. Amer. Assoc. Cancer Res., 41: 771, 2000.
61. Allegrini, G., Goulette, F.A., Darnowski, J.W. and Calabresi, P. The antiangiogenesis inhibitor thrombospondin-1 plus irinotecan significantly inhibit tumor growth in human colon tumor bearing nude mice. Proc. Amer. Assoc. Cancer Res., 41: 813, 2000.

62. Darnowski, J.W., Goulette, F.A., Wagner, E.F., Simms, E. and Calabresi, P. Taurolidine: A novel, nontoxic, antineoplastic agent that induces apoptosis in androgen-independent DU145 human prostate tumor cells. *Proc. Amer. Assoc. Cancer Res.*, 42: 212, 2001.
63. Ribizzi, I., Han, Z., Darnowski, J.W., Goulette, F.A., Wagner, E.F. and Calabresi, P. Taurolidine: Mechanism of action of a novel and safe cytotoxic agent for cancer therapy. *Proc. Amer. Assoc. Cancer Res.*, 42: 212, 2001.
64. Ribizzi, I., Darnowski, J.W., Goulette, F.A., Akhtar, M.S. and Calabresi, P. Taurolidine: A novel agent for bone marrow purging. *Proc. Amer. Assoc. Cancer Res.*, 42: 539, 2001.
65. Shroyer, D., Lukoff, H., Wagner, E., Goulette, F., Darnowski, J. and Calabresi, P. In vitro study of adherent and floating MNT-1 human melanoma cell populations developing in the presence of taurolidine. *Proc. Amer. Assoc. Cancer Res.*, 42: 545, 2001.
66. Chatterjee, D., Cousens, L.P., Darnowski, J.W., Goulette, F.A., Martin, P.B., Ribizzi, I., Sarmiento, R. and Calabresi, P. Regulation of apoptotic and survival pathways by taurolidine in human myeloma cells. *Proc. Amer. Assoc. Cancer Res.*, 43: 876, 2002.
67. Darnowski, J.W., Goulette, F.A., Chatterjee, D., Cousens, L.P., Sarmiento, R., Braastad, C., Earl, T. and Calabresi, P. Taurolidine triggers receptor-mediated apoptosis in DU145 human prostate tumor cells. *Proc. Amer. Assoc. Cancer Res.*, 43: 956, 2002.
68. Darnowski, J.W., Goulette, F.A., Cousens, L.P., Chatterjee, D., Sartore-Bianchi, A. and Calabresi, P. STAT proteins are a target of caspase-mediated cleavage during saturosporin-induced apoptosis in the DU145 human prostate tumor cell model. *Proc. Amer. Assoc. Cancer Res.*, 44: 983, 2003.
69. Chatterjee, D., Braastad, C., Goulette, F.A., Earl, T., Cousens, L.P., Calabresi, P. and Darnowski, J.W. Stat 3, a caspase target following CD95-triggered apoptosis. *Proc. Amer. Assoc. Cancer Res.*, 44: 1204, 2003.
70. Cousens, L.P., Goulette, F.A., Calabresi, P. and Darnowski, J.W. Modulation of Fas ligand-induced apoptosis by cytokine-stimulated signal transduction. *Proc. Amer. Assoc. Cancer Res.*, 44: 1293, 2003.
71. Cousens, L. P., Goulette, F. A. and Darnowski, J. W. IFN α inhibits FasL-induced apoptosis by a novel mechanism that is independent of new protein synthesis but dependent on JAK activity. *Proc. Amer. Assoc. Cancer Res.*, 45: 152, 2004.
72. Darnowski, J. W., Goulette, F. A. and Cousens, L. P. Stat3 protein is directly targeted for demolition by cellular caspases. *Proc. Amer. Assoc. Cancer Res.*, 45: 1195, 2004.

73. Chatterjee, D., Yuan, Z., Bonavida, B., Darnowski, J. and Chin, Y. E. RKIP inhibits IL-6 mediated activation of Stat3 in DU145 prostate cancer cells. *Proc. Amer. Assoc Cancer Res.*, 46: 225, 2005.
74. Darnowski, J. W., Cousens, L. P., Chatterjee, D. and Goulette, F. A. Caspase-mediated STAT protein cleavage: biochemical and functional analysis. *Proc. Amer. Assoc Cancer Res.*, 46: 632, 2005.